Holzer & Holzer, LLC informs investors that a class action lawsuit was filed against Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQ: AKBA). The lawsuit alleges, among other things, that Akebia made certain false and/or misleading statements regarding the Company’s business, operations, and prospects, including misrepresentations relating to the level of safety of vadadustat, Akebia’s kidney disease therapy, in treating certain patients, and overstating vadadustat’s overall commercial and regulatory prospects.
If you bought shares of Akebia between June 28, 2018 and September 2, 2020, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected] or Joshua Karr, Esq. at [email protected], by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com to learn more.
The deadline to ask the court to be appointed lead plaintiff in the case is May 13, 2022.
Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.
CONTACT:
Corey D. Holzer, Esq.
(888) 508-6832 (toll-free)
[email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/116904
Source: Newsfile Corp.
Release ID: 201132
There is no offer to sell, no solicitation of an offer to buy, and no recommendation of any security or any other product or service in this article. Moreover, nothing contained in this PR should be construed as a recommendation to buy, sell, or hold any investment or security, or to engage in any investment strategy or transaction. It is your responsibility to determine whether any investment, investment strategy, security, or related transaction is appropriate for you based on your investment objectives, financial circumstances, and risk tolerance. Consult your business advisor, attorney, or tax advisor regarding your specific business, legal, or tax situation.
